Clinical Trial Update: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression [Phase 3]

View source ↗

Summary

Phase 3 trial comparing INCB123667 to investigator's choice chemotherapy in platinum-resistant ovarian cancer with Cyclin E1 overexpression is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• INCB123667 (INCB123667)

Snippet

Sponsor: Incyte Corporation | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING